Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
BEAM vs FDMT: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
FDMT Captures Overall Composite Edge (51.3 HOLD vs 47.4 HOLD), While BEAM Leads 3–2 on Growth & Valuation Pillars
FDMT Overall Winner
6-Pillar Tally: BEAM 3 – 2 FDMT (1 Tie)
Matrix Metrics: BEAM 4 – 4 FDMT
As of Nov 16, 2026, 4D Molecular Therapeutics, Inc. (FDMT) captures the overall head-to-head institutional edge over Beam Therapeutics Inc. (BEAM) on higher Unified Composite conviction (51.3/100 HOLD vs. 47.4/100 HOLD) after splitting the core matrix 4–4 (led by Valuation Multiples, Balance Sheet & Cash Flow), while BEAM wins 3–2 across the 6-pillar growth and valuation breakdown. BEAM trades at $21.29 (N/M Forward P/E, -267.7% operating margin) versus FDMT at $11.65 (N/M Forward P/E, -222.7% operating margin).
- Growth vs. Quality Trade-Off: FDMT earns the overall head-to-head edge with a stronger Unified Composite Score (51.3/100 HOLD vs. BEAM 47.4/100 HOLD) and 1.89β · 90% Vol risk profile, whereas BEAM leads top-line expansion (-96.8% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
- Technical & Structure Timing Caution: BEAM is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 36.1); meanwhile FDMT is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 44.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About BEAM vs FDMT
BEAM
Beam Therapeutics Inc. Common Stock
$21.29
-6.75% 1D
Market Cap
$2.4B
TTM Revenue
$147M
Forward P/E
N/M
Beta / 30D Vol
2.24β · 86% Vol
Unified Composite Score
47.4
HOLD
Tech 34.0
Fund 54.0
Flow 70.0
Mom 70.0
Weinstein Technical Phase
Markdown · Sell / avoid
FDMT
Head-to-Head Winner
4D Molecular Therapeutics, Inc. Common Stock
$11.65
-4.74% 1D
Market Cap
$669.3M
TTM Revenue
$96M
Forward P/E
N/M
Beta / 30D Vol
1.89β · 90% Vol
Unified Composite Score
51.3
HOLD
Tech 51.0
Fund 47.0
Flow 66.0
Mom 54.0
Weinstein Technical Phase
Markdown · Sell / avoid
6-Pillar Scorecard Institutional Category Breakdown (BEAM 3 – 2 FDMT)
1. Valuation Multiples
FDMT
Forward P/E
N/M
N/M
Trailing P/E
N/M
N/M
PEG Ratio
N/M
N/M
EV / Revenue
16.8x
6.6x
2. Growth & Scale
BEAM
Revenue Growth (YoY)
-96.8%
+4505.6%
Earnings Growth (YoY)
+0.0%
+0.0%
TTM Revenue (USD)
$147M
$96M
Market Cap
$2.4B
$669.3M
3. Profitability & Quality
BEAM
Gross Margin
N/A
N/A
Operating Margin
-267.7%
-222.7%
Net Profit Margin
-73.9%
-208.6%
Return on Equity (ROE)
-11.3%
-56.7%
4. Balance Sheet & Cash Flow
FDMT
Cash Generation (TTM)
-$398M
-$156M
Cash Flow Margin
N/A
N/A
Net Cash / Leverage
$31M Net Debt (0.26x D/E)
$31M Net Cash
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
BEAM
Options Structure Phase
BREAKDOWN
BREAKDOWN
Current IV / %ile
66.0% (42nd %ile)
82.4% (10th %ile)
Put/Call OI Skew
0.47x (Call-Skewed)
5.16x (Put-Skewed)
OBV Trend / Tech Phase
DISTRIBUTION · Markdown
NEUTRAL · Markdown
6. R&D & Supply-Chain Moat
Tie
OpEx & R&D Intensity
N/A
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Biotechnology Operator
Biotechnology Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: BEAM (4) vs FDMT (4)| Institutional Metric | BEAM | FDMT | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $2.4B | $669.3M | BEAM | |
| Trailing P/E Ratio | N/M | N/M | Tie | |
| Forward P/E Ratio | N/M | N/M | Tie | |
| Revenue Growth (YoY) | -96.8% | +4505.6% | FDMT | |
| Operating Margin (TTM) | -267.7% | -222.7% | FDMT | |
| Net Profit Margin | -73.9% | -208.6% | BEAM | |
| Return on Equity (ROE) | -11.3% | -56.7% | BEAM | |
| 52-Week Range Position | 6% ($20–$38) | 47% ($7–$17) | FDMT | |
| Beta / 30D Volatility | 2.24β · 86% Vol | 1.89β · 90% Vol | BEAM | |
| Unified Institutional Score | 47.4 / 100 (HOLD) | 51.3 / 100 (HOLD) | FDMT | |
| Trailing 12M Revenue (USD) | $147M | $96M | Scale | |
| Gross Profit Margin (TTM) | N/A | N/A | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · 16.8x EV/Rev | N/M PEG · 6.6x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$398M ($31M Net Debt (0.26x D/E)) | -$156M ($31M Net Cash) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
FDMT +5.25 pp
3M Horizon
BEAM +0.99 pp
6M Horizon
FDMT +59.86 pp
1Y Horizon
FDMT +15.04 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | BEAM Revenue | FDMT Revenue | BEAM Op. Margin | FDMT Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2019 | $0M | $10M | -417522.2% | -729.4% | FDMT |
| FY2020 | $0M | $10M | -553166.7% | -424.0% | FDMT |
| FY2021 | $50M | $20M | -757.0% | -395.5% | FDMT |
| FY2022 | $60M | $0M | -555.6% | -3516.5% | BEAM |
| FY2023 | $380M | $20M | -46.7% | -544.6% | BEAM |
| FY2024 | $60M | $0M | -654.3% | -507678.4% | BEAM |
| FY2025 | $140M | $90M | -274.6% | -187.2% | FDMT |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
BEAM
BREAKDOWN
Current IV
66.0%
IV Percentile
42nd %ile
Put/Call OI Skew
0.47x (Call-Skewed)
IV Regime
Balanced (25th–60th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
DISTRIBUTION
Exact BEAM Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
FDMT
BREAKDOWN
Current IV
82.4%
IV Percentile
10th %ile
Put/Call OI Skew
5.16x (Put-Skewed)
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BEARISH
OBV Flow
NEUTRAL
Exact FDMT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
BEAM Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
FDMT Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ BEAM vs FDMT Key Questions & Quantitative Answers
As of Nov 16, 2026, 4D Molecular Therapeutics, Inc. (FDMT) captures the overall head-to-head institutional edge over Beam Therapeutics Inc. (BEAM) on higher Unified Composite conviction (51.3/100 HOLD vs. 47.4/100 HOLD) after splitting the core matrix 4–4 (led by Valuation Multiples, Balance Sheet & Cash Flow), while BEAM wins 3–2 across the 6-pillar growth and valuation breakdown. BEAM trades at $21.29 (N/M Forward P/E, -267.7% operating margin) versus FDMT at $11.65 (N/M Forward P/E, -222.7% operating margin). Growth vs. Quality Trade-Off: FDMT earns the overall head-to-head edge with a stronger Unified Composite Score (51.3/100 HOLD vs. BEAM 47.4/100 HOLD) and 1.89β · 90% Vol risk profile, whereas BEAM leads top-line expansion (-96.8% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: BEAM is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 36.1); meanwhile FDMT is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 44.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
BEAM leads the Growth & Scale pillar: BEAM posts -96.8% YoY revenue growth and +0.0% YoY earnings growth on $147M TTM revenue (N/A gross margin, -267.7% operating margin), compared with FDMT at +4505.6% YoY revenue growth and +0.0% YoY earnings growth on $96M TTM revenue (N/A gross margin, -222.7% operating margin). Across the 7-period historical trajectory (FY2019 to FY2025), BEAM cumulative revenue shifted +180.0% while FDMT shifted +800.0%. In operating R&D and SG&A reinvestment, BEAM deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for FDMT.
FDMT screens cheaper on headline valuation multiples. BEAM trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 16.8x EV/Revenue (unreported FCF margin), whereas FDMT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 6.6x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against BEAM (-11.3% ROE) versus FDMT (-56.7% ROE) capital efficiency.
In options market volatility and institutional positioning, BEAM carries 66.0% implied volatility (42nd %ile, Balanced (25th–60th %ile)), a 0.47x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (2.24β · 86% Vol realized risk). By comparison, FDMT carries 82.4% implied volatility (10th %ile, Compressed (<25th %ile)), a 5.16x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.89β · 90% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
FDMT vs BEAM · Reverse Pair
BEAM vs NTLA
· Sector Peer
BEAM vs TWST
· Sector Peer
BEAM vs CRSP
· Sector Peer
FDMT vs STOK
· Sector Peer
FDMT vs ANNX
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem